Preclinical studies have shown that the AMG330′s anti-CD33 x anti-CD3 construct is cytotoxic even when target cells have low CD33 antigen density, making it a candidate to target a wide variety of CD33-positive leukemia including AML. Here, CD33 is linked to acute myeloid leukemia.